[{"data":1,"prerenderedAt":33},["ShallowReactive",2],{"$fc8XxPcTax5fT2QSA9-xqrNVSWvrIhx0hYzvWo2aZKB4":3},{"code":4,"show":5,"msg":6,"data":7,"status":32},1,0,"",{"lists":8,"count":13,"page_no":4,"page_size":30,"extend":31},[9,18,25],{"publish_time":10,"cate_name":11,"id":12,"cid":13,"title":14,"desc":15,"image":16,"publish_at":17},"2026-04-14","好物",4,3,"SciBrunch Therapeutics Completes Over  35 Million Pre-A Round Financing, Totaling 65 Million in Two Recent Rounds","SciBrunch Therapeutics announced the completion of an oversubscribed Pre-A round financing of over $35 million.","https://api-scibrunch.hellokoma.com/uploads/images/20260416/20260416153543a1ff13477.jpg",1776149657,{"publish_time":19,"cate_name":20,"id":13,"cid":4,"title":21,"desc":22,"image":23,"publish_at":24},"2026-04-09","科技","First Patient In! SciBrunch Initiates Phase I Clinical Trial of Highly Selective PARP1 Inhibitor SPR1020","SciBrunch Therapeutics announced that the Phase I/II clinical trial of SPR1020 for advanced solid tumors, co-led by the Cancer Hospital of the Chinese Academy of Medical Sciences and Harbin Medical","https://api-scibrunch.hellokoma.com/uploads/images/20260416/202604161535589162c2350.jpg",1775712313,{"publish_time":19,"cate_name":11,"id":4,"cid":13,"title":26,"desc":27,"image":28,"publish_at":29},"SciBrunch Therapeutics Completes Over RMB 200 Million Angel Round Financing, Focused on Innovative Small-Molecule Oncology Drugs","SciBrunch Therapeutics recently announced the completion of an angel round financing of over RMB 200 million. The round was co-led by BioTrack Capital and HanKang Capital, with participation from Elik","https://api-scibrunch.hellokoma.com/uploads/images/20260416/20260416153610f29df5455.jpg",1775712312,8,{"total":13},200,1776763000811]